Pfizer cancer drug fails in 2 late-stage studies
http://gazette.com/pfizer-cancer-drug-fails-in-2-late-stage-studies/article/feed/82455
Pfizer cancer drug fails in 2 late-stage studies
Updated: January 27, 2014 at 7:47 am Published: January 27, 2014
NEW YORK (AP) A potential Pfizer Inc. treatment for an advanced form of lung cancer missed its main goals in two late-stage studies, but the drugmaker said it is still waiting for results from a third study.
The New York company said Monday that dacomitinib failed to show a statistically significant improvement in progression-free survival in a study comparing it with the treatment erlotinib. It also missed its goal of prolonging overall survival when compared to a fake drug or a placebo in another study.
Both clinical trials involved patients with advanced non-small cell lung cancer who had tried other treatments. Progression-free survival measures the time from the start of treatment until a patient's cancer begins advancing again or the patient dies.
Dacomitinib also is being compared to another treatment, gefitinib, in a third, late-stage study involving patients who had no prior treatment. Results from that are expected next year.